1. Home
  2. FAMI vs XRTX Comparison

FAMI vs XRTX Comparison

Compare FAMI & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Farmmi Inc.

FAMI

Farmmi Inc.

N/A

Current Price

$0.10

Market Cap

4.6M

ML Signal

N/A

Logo XORTX Therapeutics Inc.

XRTX

XORTX Therapeutics Inc.

N/A

Current Price

$1.09

Market Cap

3.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FAMI
XRTX
Founded
2015
2011
Country
China
Canada
Employees
N/A
N/A
Industry
Packaged Foods
Pharmaceuticals and Biotechnology
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
3.9M
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
FAMI
XRTX
Price
$0.10
$1.09
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 808.0K
347.2K
Earning Date
08-27-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$392.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.09
$0.35
52 Week High
$1.85
$3.60

Technical Indicators

Market Signals
Indicator
FAMI
XRTX
Relative Strength Index (RSI) 36.13 36.68
Support Level $0.09 $0.37
Resistance Level $0.20 $2.26
Average True Range (ATR) 0.01 0.25
MACD -0.00 -0.03
Stochastic Oscillator 13.99 19.84

Price Performance

Historical Comparison
FAMI
XRTX

About FAMI Farmmi Inc.

Farmmi Inc is an investment holding company. Through its subsidiaries, it acts as a supplier of agricultural products. It is an agricultural technology enterprise focused on its supply chain platform by promoting edible mushroom products and agriculture technology. Its product offerings include tapioca, corn, red dates, shiitake mushrooms, mu er fungus, other edible fungi, and other agricultural products. Geographically, the company's products are sold in China, Southeast Asia, Japan, North America, Europe and the Middle East under the Forasen and Farmmi brands.

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.

Share on Social Networks: